NCT02146248View on ClinicalTrials.gov

HSG and Tubal Patency Study

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

April 30, 2015

Conditions
Tubal Patency
Interventions
DRUG

combined oral contraceptive

combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption

DRUG

DepoProvera

injectable hormonal contraceptive

Trial Locations (1)

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Jeffrey Jensen

OTHER

NCT02146248 - HSG and Tubal Patency Study | Biotech Hunter | Biotech Hunter